AXP
0.018
38.5%
ZNO
0.093
-40%
APL
0.15
36.4%
RAN
0.002
-33.3%
TMKDD
0.15
36.4%
TPG
3.8
-32.1%
BIT
0.004
33.3%
CMG
0.13
-23.5%
GAS
0.03
30.4%
RWD
0.039
-20.4%
MTB
0.014
27.3%
8IH
0.018
-18.2%
CAV
0.005
25%
NVA
1.195
-17.6%
FBM
0.064
23.1%
AKN
0.005
-16.7%
EGR
0.545
22.5%
AVL
0.01
-16.7%
HAR
0.165
22.2%
IPT
0.005
-16.7%
RCR
0.017
21.4%
SHP
0.03
-16.7%
OM1
0.023
21.1%
VAR
0.005
-16.7%
HE8
0.012
20%
RXL
0.38
-16.5%
LGM
0.25
19%
REC
0.016
-15.8%
IS3
0.019
18.8%
BLG
0.011
-15.4%
KFM
0.09
18.4%
IRI
0.305
-15.3%
CHR
0.1
17.6%
AVE
0.006
-14.3%
NXD
0.41
17.1%
BNL
0.006
-14.3%
AHK
0.525
16.7%
M4M
0.006
-14.3%
MGU
0.007
16.7%
PLC
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759